AAAAAA
Results:
1-12
|
Results: 12
Authors:
Konecny, G
Untch, M
Arboleda, J
Wilson, C
Kahlert, S
Boettcher, B
Felber, M
Beryt, M
Lude, S
Hepp, H
Slamon, D
Pegram, M
Citation: G. Konecny et al., HER-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer, CLIN CANC R, 7(8), 2001, pp. 2448-2457
Authors:
Konecny, G
Untch, M
Pihan, A
Kimmig, R
Gropp, M
Stieber, P
Hepp, H
Slamon, D
Pegram, M
Citation: G. Konecny et al., Association of urokinase-type plasminogen activator and its inhibitor withdisease progression and prognosis in ovarian cancer, CLIN CANC R, 7(6), 2001, pp. 1743-1749
Authors:
Poiesz, BJ
Papsidero, LD
Ehrlich, G
Sherman, M
Dube, S
Poiesz, M
Dillon, K
Ruscetti, FW
Slamon, D
Fang, C
Williams, A
Duggan, D
Glaser, J
Gottlieb, A
Goldberg, J
Ratner, L
Phillips, P
Han, T
Friedman-Kien, A
Siegal, F
Rai, K
Sawitsky, A
Sheremata, LWA
Dosik, H
Cunningham, C
Montagna, R
Citation: Bj. Poiesz et al., Prevalence of HTLV-I-associated T-cell lymphoma, AM J HEMAT, 66(1), 2001, pp. 32-38
Authors:
Konecny, G
Fritz, M
Untch, M
Lebeau, A
Felber, M
Lude, S
Beryt, M
Hepp, H
Slamon, D
Pegram, M
Citation: G. Konecny et al., HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer, BREAST CANC, 69(1), 2001, pp. 53-63
Authors:
Konecny, G
Untch, M
Slamon, D
Beryt, M
Kahlert, S
Felber, M
Langer, E
Lude, S
Hepp, H
Pegram, M
Citation: G. Konecny et al., Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples, BREAST CANC, 67(3), 2001, pp. 223-233
Authors:
Nabholtz, JM
Slamon, D
Citation: Jm. Nabholtz et D. Slamon, New adjuvant strategies for breast cancer: Meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin), SEMIN ONCOL, 28(1), 2001, pp. 1-12
Authors:
Slamon, D
Pegram, M
Citation: D. Slamon et M. Pegram, Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials, SEMIN ONCOL, 28(1), 2001, pp. 13-19
Authors:
Singer, E
Landgraf, R
Horan, T
Slamon, D
Eisenberg, D
Citation: E. Singer et al., Identification of a heregulin binding site in HER3 extracellular domain, J BIOL CHEM, 276(47), 2001, pp. 44266-44274
Authors:
Lackey, DB
Groziak, MP
Sergeeva, M
Beryt, M
Boyer, C
Stroud, RM
Sayre, P
Park, JW
Johnston, P
Slamon, D
Shepard, HM
Pegram, M
Citation: Db. Lackey et al., Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase, BIOCH PHARM, 61(2), 2001, pp. 179-189
Authors:
Konecny, G
Pegram, M
Slamon, D
Citation: G. Konecny et al., Docetaxel and trastuzumab: A combination with clinical relevance, ONKOLOGIE, 23, 2000, pp. 7-9
Authors:
Pegram, M
Slamon, D
Citation: M. Pegram et D. Slamon, Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy, SEMIN ONCOL, 27(5), 2000, pp. 13-19
Authors:
Pegram, M
Hsu, S
Lewis, G
Pietras, R
Beryt, M
Sliwkowski, M
Coombs, D
Baly, D
Kabbinavar, F
Slamon, D
Citation: M. Pegram et al., Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers, ONCOGENE, 18(13), 1999, pp. 2241-2251
Risultati:
1-12
|